{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:17:20Z","timestamp":1771931840033,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Chronic myeloid leukemia (CML) is driven by the\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      fusion gene. Although tyrosine kinase inhibitors (TKIs) have transformed outcomes, treatment resistance persists. Plasma extracellular vesicles (EVs) reflect their cell of origin and may serve as stable biomarkers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To characterize the plasma EV proteome in CML patients with distinct treatment responses and T315I mutation status. EVs were isolated from the plasma of healthy controls (HC) and CML patients classified as good (GTR) or poor (PTR) treatment responders, treatment-free remission (TFR), and T315I or pre-T315I mutation carriers. EVs were purified by size-exclusion chromatography, characterized by NTA and TEM, and analyzed by label-free mass spectrometry, followed by differential expression, enrichment, and protein\u2013protein interaction analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 598 proteins were identified, 257 retained after quality and abundance filtering. Forty-two proteins were differentially expressed among HC, GTR, and PTR groups (p &amp;lt; 0.01), with PTR 27 samples showing marked downregulation of cytoskeletal and chaperone proteins (such as MYH9, 28 HSP90AB1, FERMT3). TFR patients exhibited distinct enrichment in complement and coagulation cascades (C3, C4B, F9, F11) and metabolic pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Plasma EV proteomes reflect CML clinical status, revealing immune and cytoskeletal alterations associated with treatment response, remission, and resistance, suggesting potential biomarkers for disease monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgene.2026.1762244","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T22:10:24Z","timestamp":1771193424000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Differentially expressed proteins in plasma-derived extracellular vesicles from chronic myeloid leukemia patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Denise","family":"Kusma Wosniaki","sequence":"first","affiliation":[{"name":"Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz)","place":["Curitiba, State of Paran\u00e1, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre Luiz","family":"Korte de Azevedo","sequence":"additional","affiliation":[{"name":"Department of Genetics, Federal University of Paran\u00e1","place":["Curitiba, State of Paran\u00e1, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anelis Maria","family":"Marin","sequence":"additional","affiliation":[{"name":"Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz)","place":["Curitiba, State of Paran\u00e1, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis Germ\u00e1n","family":"Murillo Carrasco","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o Translacional em Oncologia (LIM24), Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), Faculdade de Medicina da Universidade de S\u00e3o Paulo (FMUSP)","place":["S\u00e3o Paulo, S\u00e3o Paulo, Brazil"]},{"name":"Comprehensive Center for Precision Oncology, Universidade de S\u00e3o Paulo","place":["S\u00e3o Paulo, S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Nogueira de Sousa Andrade","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o Translacional em Oncologia (LIM24), Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), Faculdade de Medicina da Universidade de S\u00e3o Paulo (FMUSP)","place":["S\u00e3o Paulo, S\u00e3o Paulo, Brazil"]},{"name":"Comprehensive Center for Precision Oncology, Universidade de S\u00e3o Paulo","place":["S\u00e3o Paulo, S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Brant","sequence":"additional","affiliation":[{"name":"Mass Spectrometry Facility RPT02H, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz)","place":["Curitiba, State of Paran\u00e1, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Batista","sequence":"additional","affiliation":[{"name":"Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz)","place":["Curitiba, State of Paran\u00e1, Brazil"]},{"name":"Mass Spectrometry Facility RPT02H, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz)","place":["Curitiba, State of Paran\u00e1, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talita Helen","family":"Bombardelli Gomig","sequence":"additional","affiliation":[{"name":"Department of Genetics, Federal University of Paran\u00e1","place":["Curitiba, State of Paran\u00e1, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Chammas","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o Translacional em Oncologia (LIM24), Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), Faculdade de Medicina da Universidade de S\u00e3o Paulo (FMUSP)","place":["S\u00e3o Paulo, S\u00e3o Paulo, Brazil"]},{"name":"Comprehensive Center for Precision Oncology, Universidade de S\u00e3o Paulo","place":["S\u00e3o Paulo, S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateus","family":"N\u00f3brega Aoki","sequence":"additional","affiliation":[{"name":"Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz)","place":["Curitiba, State of Paran\u00e1, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalila Luc\u00edola","family":"Zanette","sequence":"additional","affiliation":[{"name":"Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz)","place":["Curitiba, State of Paran\u00e1, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1239042","DOI":"10.3389\/fonc.2023.1239042","article-title":"Extracellular vesicles in the chronic myeloid leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules","volume":"13","author":"Bernardi","year":"2024","journal-title":"Front. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12967-025-06434-1","article-title":"LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth","volume":"23","author":"Cela","year":"2025","journal-title":"J. Transl. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.molimm.2018.05.018","article-title":"Properdin: a multifaceted molecule involved in inflammation and diseases","volume":"102","author":"Chen","year":"2018","journal-title":"Mol. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.2147\/CMAR.S232752","article-title":"Monitoring of minimal residual disease (Mrd) in chronic myeloid leukemia: recent advances","volume":"12","author":"Cumbo","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-030-23158-3_1","article-title":"Regulatory roles of HSP90-Rich extracellular vesicles","author":"Eguchi","year":"2019"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-Seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinforma."},{"key":"B7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/15257770.2023.2296021","article-title":"Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a bioinformatics study","volume":"43","author":"Hekmatshoar","year":"2024","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41375-023-02074-w","article-title":"Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation","volume":"38","author":"Huuhtanen","year":"2024","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s12185-010-0590-0","article-title":"Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation","volume":"91","author":"Ieko","year":"2010","journal-title":"Int. J. Hematol."},{"key":"B11","article-title":"Global cancer observatory, Globocan. Globocan 2022","year":"2022"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2147\/OTT.S371847","article-title":"Molecular changes in chronic myeloid leukemia during tyrosine kinase inhibitors treatment. Focus on immunological pathways","volume":"15","author":"Janowski","year":"2022","journal-title":"Onco Targets Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.3390\/jcm13082353","article-title":"The depth of the molecular response in patients with chronic myeloid leukemia correlates with changes in humoral immunity","volume":"13","author":"Janowski","year":"2024","journal-title":"J. Clin. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.1016\/j.ymthe.2025.08.048","article-title":"CFHR2 supplementation mitigates pathologies of neuromyelitis optica by regulating complement activation","volume":"33","author":"Jiang","year":"2025","journal-title":"Mol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1001450","DOI":"10.1371\/journal.pbio.1001450","article-title":"Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation","volume":"10","author":"Kalra","year":"2012","journal-title":"PLoS Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fimmu.2018.00721","article-title":"Extracellular vesicles: packages sent with complement","volume":"9","author":"Karasu","year":"2018","journal-title":"Front. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jmb.2015.09.019","article-title":"ExoCarta: a web-based compendium of exosomal cargo","volume":"428","author":"Keerthikumar","year":"2016","journal-title":"J. Mol. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1443346","DOI":"10.3389\/fonc.2024.1443346","article-title":"Expression of HOTAIR and PTGS2 as potential biomarkers in chronic myeloid leukemia patients in Brazil","volume":"14","author":"Kubaski Benevides","year":"2024","journal-title":"Front. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"779567","DOI":"10.3389\/fonc.2021.779567","article-title":"Quantitative proteomic analysis of plasma exosomes to identify the candidate biomarker of imatinib resistance in chronic myeloid leukemia patients","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.21037\/apm-20-343","article-title":"Systematic analysis reveals a lncrna-mirna-mrna network associated with dasatinib resistance in chronic myeloid leukemia","volume":"10","author":"Luo","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"10118","DOI":"10.3390\/ijms241210118","article-title":"Molecular BCR::ABL1 quantification and ABL1 mutation detection as essential tools for the clinical management of chronic myeloid leukemia patients: results from a Brazilian single-center study","volume":"24","author":"Marin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70901","DOI":"10.1111\/jcmm.70901","article-title":"Assessment of chronic myeloid leukaemia in vitro models variability: insights into extracellular vesicles","volume":"29","author":"Mutti","year":"2025","journal-title":"J. Cell Mol. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1002\/jcb.27039","article-title":"HSP-enriched properties of extracellular vesicles involve survival of metastatic oral cancer cells","volume":"119","author":"Ono","year":"2018","journal-title":"J. Cell Biochem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"100825","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11899-023-00688-6","article-title":"The bone marrow immune microenvironment in CML: treatment responses, treatment-free remission, and therapeutic vulnerabilities","volume":"18","author":"Patterson","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12964-021-00752-9","article-title":"Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells","volume":"19","author":"Peng","year":"2021","journal-title":"Cell Commun. Signal"},{"key":"B28","doi-asserted-by":"publisher","first-page":"18491","DOI":"10.1038\/srep18491","article-title":"Kindlin-3 interacts with the ribosome and regulates c-Myc expression required for proliferation of chronic myeloid leukemia cells","volume":"5","author":"Qu","year":"2015","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1241600","DOI":"10.3389\/fimmu.2023.1241600","article-title":"In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy","volume":"14","author":"Sanchez","year":"2023","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"7605","DOI":"10.3390\/ijms25147605","article-title":"Cellular in vitro responses induced by human mesenchymal stem\/stromal cell-derived extracellular vesicles obtained from suspension culture","volume":"25","author":"Souza","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: customizable protein\u2013protein networks, and functional characterization of user-uploaded gene\/measurement sets","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/1440-1681.13685","article-title":"Blockage of PD-L1 by FERMT3-mediated Wnt\/\u03b2-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells","volume":"49","author":"Tang","year":"2022","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","article-title":"The perseus computational platform for comprehensive analysis of (prote)omics data","volume":"13","author":"Tyanova","year":"2016","journal-title":"Nat. Methods"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.3390\/ijms25063363","article-title":"The screening of microRNAs in chronic myeloid leukemia: a clinical evaluation","volume":"25","author":"Wosniaki","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1556956","DOI":"10.3389\/fonc.2025.1556956","article-title":"Divergent gene expression of PTGS1 and PTGS2 along the disease course of chronic myeloid leukaemia","volume":"15","author":"Wosniaki","year":"2025","journal-title":"Front. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.bcmd.2012.11.002","article-title":"Hsp90 - a potential prognostic marker in CML","volume":"50","author":"Z\u00e1\u010dkov\u00e1","year":"2013","journal-title":"Blood Cells Mol. Dis."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1762244\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:31:08Z","timestamp":1771929068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1762244\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":39,"alternative-id":["10.3389\/fgene.2026.1762244"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2026.1762244","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"article-number":"1762244"}}